Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Mei Pharma Inc
(NQ:
MEIP
)
3.140
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Mei Pharma Inc
< Previous
1
2
3
4
5
6
7
Next >
10 Biggest Price Target Changes For Friday
March 25, 2022
Jefferies cut the price target on MEI Pharma, Inc. (NASDAQ: MEIP) from $4 to $1. MEI Pharma shares fell 44.2% to $1.01 in pre-market trading.
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
March 25, 2022
Good morning, trader! Get ready for one more busy day of investing today with the biggest pre-market stock movers for Friday!
Via
InvestorPlace
34 Stocks Moving in Friday's Pre-Market Session
March 25, 2022
Gainers Clever Leaves Holdings Inc. (NASDAQ: CLVR) rose 40.5% to $2.22 in pre-market trading after the company reported better-than-expected Q4 sales results and reaffirmed FY22...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
March 24, 2022
Gainers
Via
Benzinga
Why MEI Pharma Stock Is Plummeting After Hours
March 24, 2022
MEI Pharma Inc (NASDAQ: MEIP) shares are plunging in Thursday's after-hours session after the company provided an investor update following a recent meeting with the U.S...
Via
Benzinga
MEI Pharma and Kyowa Kirin Provide Regulatory Update on Zandelisib Following Meeting with the FDA
March 24, 2022
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma's Return On Capital Employed Insights
February 14, 2022
According to data from Benzinga Pro, during Q2, MEI Pharma's (NASDAQ:MEIP) reported sales totaled $18.22 million. Despite a 51.46% increase in earnings, the company posted a loss of $5.77 million.
Via
Benzinga
Recap: MEI Pharma Q2 Earnings
February 11, 2022
MEI Pharma (NASDAQ:MEIP) reported its Q2 earnings results on Thursday, February 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings MEI Pharma beat estimated...
Via
Benzinga
MEI Pharma Reports Second Quarter Fiscal Year 2022 Results and Operational Highlights
February 10, 2022
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma Strengthens Clinical and Quality Expertise with New Key Executive Appointments
February 07, 2022
From
MEI Pharma, Inc.
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For February 3, 2022
February 03, 2022
Upgrades BTIG upgraded the previous rating for Insulet Corp (NASDAQ:PODD) from Neutral to Buy. For the third quarter, Insulet had an EPS of $0.18, compared to year-ago...
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
February 03, 2022
On Thursday, 105 stocks hit new 52-week lows. Interesting Highlights From Today's 52-Week Lows And Highs: Meta Platforms (NASDAQ:FB) was the biggest company on...
Via
Benzinga
MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
February 01, 2022
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 03, 2022
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma Announces Closing of Public Offering of Common Stock
December 06, 2021
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
December 03, 2021
From
MEI Pharma, Inc.
Via
Business Wire
61 Biggest Movers From Yesterday
December 03, 2021
Gainers Jowell Global Ltd. (NASDAQ: JWEL) jumped 25.5% to close at $13.36. Jowell Global recently announced a collaboration with Unilever's Uni-Excubator. Information...
Via
Benzinga
MEI Pharma Raises $45M Via Equity Issued At 14% Discount
December 02, 2021
MEI Pharma Inc (NASDAQ: MEIP) priced the underwritten public offering of 17.5 million shares at $2.60/share for gross proceeds of $45.5 million. The offer price...
Via
Benzinga
40 Stocks Moving In Thursday's Mid-Day Session
December 02, 2021
Gainers Biofrontera Inc. (NASDAQ: BFRI) surged 39% to $6.02. Biofrontera announced Notice of Allowance for U.S. patent titled 'Illumination for Photodynamic Therapy.'...
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
MEI Pharma Announces Pricing of Public Offering of Common Stock
December 01, 2021
From
MEI Pharma, Inc.
Via
Business Wire
The Daily Biotech Pulse: Adcom Backs Merck's Oral COVID-19 Treatment; Regulatory Setbacks For CTI Biopharma, BioXcel; Favorable Ruling For Viatris In Tecfidera Patent Case
December 01, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Adcom Backing For Oral COVID-19 Antiviral Medication Molnupiravir...
Via
Benzinga
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
12 Health Care Stocks Moving In Tuesday's Intraday Session
November 30, 2021
Gainers Cumberland (NASDAQ:CPIX) stock...
Via
Benzinga
52 Biggest Movers From Yesterday
December 01, 2021
Gainers Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) shares climbed 128.6% to close at $5.03 on Tuesday. The FDA approved expanded labeling for Cumberland...
Via
Benzinga
Exposures
Product Safety
MEI Pharma Announces Proposed Public Offering of Common Stock
November 30, 2021
From
MEI Pharma, Inc.
Via
Business Wire
Mid-Afternoon Market Update: Dow Dips 500 Points; ImmunoGen Shares Spike Higher
November 30, 2021
Toward the end of trading Tuesday, the Dow traded down 1.44% to 34,628.69 while the NASDAQ fell 1.34% to 15,571.16. The S&P also fell, dropping 1.36% to 4,592.03. The U.S. has...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
35 Stocks Moving In Tuesday's Mid-Day Session
November 30, 2021
Gainers Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) shares jumped 105.9% to $4.53. The FDA approved expanded labeling for Cumberland Pharmaceuticals’ Caldolor, an...
Via
Benzinga
Exposures
Product Safety
MEI Pharma, Kyowa Kirin Reveal Data From Zandelisib Trial In Follicular Lymphoma
November 30, 2021
MEI Pharma Inc (NASDAQ: MEIP) and Kyowa Kirin Co Ltd have announced data from the pivotal Phase 2 TIDAL study of zandelisib as a single agent for follicular...
Via
Benzinga
The Daily Biotech Pulse: Cumberland Jumps On FDA Nod, Regeneron Says Antibody Treatment May Be Less Effective Against Omicron, ImmunoGen Readout
November 30, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Cumberland Gets FDA Approval For IV-Delivered Ibuprofen For Use In Pre-...
Via
Benzinga
Exposures
Product Safety
MEI Pharma and Kyowa Kirin Announce Data From the Ongoing Global Phase 2 TIDAL Study Evaluating Zandelisib as a Single Agent in Patients with Relapsed or Refractory Follicular Lymphoma
November 30, 2021
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma to Host Webcast on November 30, 2021 at 8:00 a.m. ET Reporting Data from Ongoing Global Phase 2 TIDAL Study of Zandelisib in Patients with Follicular Lymphoma
November 29, 2021
From
MEI Pharma, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.